Back to top
more

Global Blood Therapeutics, Inc. (GBT)

(Delayed Data from NSDQ)

$55.18 USD

55.18
646,468

+1.34 (2.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $55.12 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates

Global Blood (GBT) delivered earnings and revenue surprises of -3.09% and 6.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Global Blood Therapeutics (GBT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Global Blood's (GBT) MAA for Oxbryta Accepted in Europe

Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.

New Strong Sell Stocks for January 6th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

New Strong Sell Stocks for December 15th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Why Is Global Blood (GBT) Down 27.3% Since Last Earnings Report?

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sanofi (SNY) Blood Disorder Candidate Gets FDA's Rejection

The FDA gives a complete response letter to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease.

Global Blood Therapeutics (GBT) Surges: Stock Moves 6.9% Higher

Global Blood Therapeutics (GBT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Global Blood (GBT) Q3 Loss Wider Than Expected, Sales Miss

Global Blood (GBT) reports a wider-than-expected loss and misses sales estimates in the third quarter of 2020.

Global Blood Therapeutics (GBT) Reports Q3 Loss, Lags Revenue Estimates

Global Blood (GBT) delivered earnings and revenue surprises of -34.72% and -17.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status

GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.

Sanofi's Dupixent Gets Breakthrough Status for New Indication

Sanofi's (SNY) blockbuster drug, Dupixent gets Breakthrough Therapy designation from the FDA as potential treatment for eosinophilic esophagitis.

Why Is Global Blood (GBT) Down 5.6% Since Last Earnings Report?

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Global Blood Therapeutics (GBT) Reports Q2 Loss, Tops Revenue Estimates

Global Blood (GBT) delivered earnings and revenue surprises of 27.12% and 67.11%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Nalak Das headshot

Top 7 Stocks Set to Beat on Earnings Today After Market

Seven top-ranked companies are poised to beat on earnings today after the closing bell.

Global Blood to Seek Approval of Oxbryta in Europe for SCD

Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.

Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD

Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.

Global Blood (GBT) Down 16.3% Since Last Earnings Report: Can It Rebound?

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

How Global Blood Therapeutics (GBT) Stock Stands Out in a Strong Industry

Global Blood Therapeutics (GBT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Sanofi's Blood Disorder Candidate Gets FDA's Priority Review

The FDA grants priority review to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD).

Global Blood Therapeutics (GBT) Reports Q1 Loss, Tops Revenue Estimates

Global Blood (GBT) delivered earnings and revenue surprises of 18.37% and 268.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Should You Global Blood (GBT) Ahead of Earnings?

Global Blood (GBT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Is Global Blood (GBT) Down 15% Since Last Earnings Report?

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Global Blood (GBT) Q4 Earnings Miss, Voxelotor Gets FDA Nod

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2019. The FDA approves voxelotor (Oxbryta) for the treatment of SCD in adults, and children 12 years of age and older.

Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates

Global Blood (GBT) delivered earnings and revenue surprises of -41.80% and 311.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?